Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | CD63 | P08962 | 3/20 | 0.32 |
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576816 | 0.82 | L3MBTL1 (0.67) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| Hydrochloric Acid SCHEMBL1369700 | 0.80 | L3MBTL1 (0.65) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL30871010 | 0.79 | NUDT1 (0.50) | L3MBTL1NUDT1HTR2CPIK3R1PIK3CA | |
| SCHEMBL3847774 | 0.78 | L3MBTL1 (0.62) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL12144260 | 0.78 | L3MBTL1 (0.62) | L3MBTL1NUDT1HTR2CPIK3R1PIK3CA | |
| SCHEMBL15007643 | 0.78 | L3MBTL1 (0.62) | L3MBTL1NUDT1HTR2CHTR2AAPP | |
| SCHEMBL1348141 | 0.78 | L3MBTL1 (0.62) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL1348114 | 0.78 | L3MBTL1 (1.00) | L3MBTL1NUDT1HTR2CHTR2AADORA2A | |
| SCHEMBL14382231 | 0.78 | L3MBTL1 (0.57) | L3MBTL1NUDT1HTR2CHTR2ASYK | |
| Hydrochloric Acid SCHEMBL1367208 | 0.77 | L3MBTL1 (0.61) | L3MBTL1NUDT1HTR2CPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359611-A | Imidazo [1,2-a ] pyridine derivative and preparation method and application thereof | 郑州大学 | 2024-07-19 | — | — | CN | claimed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4694686-A1 | FUNGICIDAL COMPOSITIONS | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024213720-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| CN-118359611-A | Imidazo [1,2-a ] pyridine derivative and preparation method and application thereof | 郑州大学 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024121013-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| WO-2009077334-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077334-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-7452902-B2 | Imidazopyridines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452902-B2 | Imidazopyridines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1931641-A2 | NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHI | SCHERING CORPORATION (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1539756-B1 | IMIDAZOPYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070066621-A1 | Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066621-A1 | Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| WO-2007032936-A2 | AZAFUSED CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | L3MBTL1 3916/4885NUDT1 1160/4885HTR2C 283/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | L3MBTL1 4087/4885NUDT1 2372/4885HTR2C 161/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | L3MBTL1 1752/4885NUDT1 2665/4885HTR2C 1598/4885 |
| US-20070066621-A1 | Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors | CDK4, CDK2, CDK5 | L3MBTL1 3797/4885NUDT1 1625/4885HTR2C 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.